This acquisition builds on a successful partnership between the two companies, helping meet a critical market gap in early-phase clinical trial supply. The facility in Boonton, New Jersey—now part of Aptar’s operations—is FDA-inspected and houses cGMP cleanrooms, suites for high-potency APIs and biologics, and advanced fill-finish technologies.
Aptar Pharma | 16/07/2025 | By Darshana | 150
Aptar Pharma Acquires Device Technology Assets of SipNose
SipNose offers a variety of devices that are designed and adapted to fit a wide range of therapies and offer the opportunity to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.
Aptar Pharma | 10/10/2024 | By Aishwarya | 255
Aptar Pharma Partners with Pulmotree to Develop Kolibri NPLI Platform
As part of the agreement, Aptar Pharma will provide PULMOTREE with their full support to accelerate growth, be the main point of contact for customers, and have the ability to complement the Kolibri NPLI Platform Technology with Aptar’s suite of comprehensive services.
Aptar Pharma | 10/09/2024 | By Aishwarya | 296
Aptar Pharma Gets NMPA Nod for Airless Drug Delivery System
Aptar Pharma has received approval by the National Medical Products Administration (NMPA) in China of Sinomune Pharmaceutical’s Li Fu metronidazole gel.
Aptar Pharma | 11/04/2024 | By Aishwarya | 538
Aptar Pharma launches first metal-free nasal spray pump
Specifically designed for recyclability, APF Futurity is Aptar Pharma’s first highly recyclable nasal spray pump
Aptar Pharma | 31/01/2023 | By Sudeep Soparkar | 685
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy